Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00224419 · ClinicalTrials.gov registry record · Phase 4
Testing Pharmacological Therapies for Pregnant Smokers
A Phase 4 study, sponsored by Duke University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 181
- Enrollment target
NCT00224419: Clinical Trial Phase 4 study, sponsored by Duke University.
NCT00224419 is a Phase 4 study that was terminated before completion, run by Duke University. The registered enrollment target is 181 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (65% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00224419, a Phase 4 study, was terminated before completion, sponsored by Duke University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 181 participants
- Enrollment target
Study Summary
Nicotine dependence has not been sufficiently addressed in current state-of-the-science cessation interventions for pregnant smokers. The weight of the evidence from the general population of smokers suggests that nicotine replacement therapies may be beneficial cessation aids for pregnant smokers who are unable to stop smoking. The tremendous potential of these therapies for promoting smoking cessation among pregnant women creates a pressing need for decision tools and protocols to encourage treatment adherence that is essential for rigorous evaluation of the effectiveness of OTC NRT when provided as part of prenatal care. The results of this research could be directly translated to the improvement of obstetrical care providers' clinical practices. Medically supervised use of OTC NRT by pregnant smokers is an alternative to continued smoking that has the potential to substantially increase rates of smoking cessation during pregnancy.
Interventions
- BEHAVIORAL Motivational interviewing for smoking cessation
- BEHAVIORAL Cognitive behaviors therapy
- DRUG CBT + NRT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 181 participants |
| Start Date | 2003-06 |
| Phase | Phase 4 |
Why NCT00224419 stopped before completion
NCT00224419 is an interventional study that assigns participants to a tested intervention. The registered 181 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (65% lower).
The record links to 0 conditions, and to 3 interventions - of which Motivational interviewing for smoking cessation is the first listed.
NCT00224419 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00224419 about?
NCT00224419 is a clinical study titled "Testing Pharmacological Therapies for Pregnant Smokers". Nicotine dependence has not been sufficiently addressed in current state-of-the-science cessation interventions for pregnant smokers. The weight of the evidence from the general population of smokers suggests that nicotine replacement therapies may be beneficial cessation aids for pregnant smokers w...
What is the current status of trial NCT00224419?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 181 participants. The study started on 2003-06.
What interventions are being tested in trial NCT00224419?
The interventions under investigation include: Motivational interviewing for smoking cessation (BEHAVIORAL), Cognitive behaviors therapy (BEHAVIORAL), CBT + NRT (DRUG).
Who is sponsoring clinical trial NCT00224419?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00224419's enrollment target sits among peer trials
181 464th of 2000 higher than 1,535 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04578392 · 181 participants · NA
MeSenteric SpAring Versus High Ligation Ileocolic Resection for the Prevention of REcurrent Crohn's DiseaSe (SPARES)
- NCT05597891 · 181 participants · NA
Endovascular Engineering ENGULF Study
- NCT03897998 · 182 participants · Phase 2
Neural Correlates of Hypoalgesia Driven by Observation
- NCT04300556 · 182 participants · Phase 1
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia